Small Is­raeli biotech flops a PhI­II test in post-surgery in­fec­tions — shares crushed

A small Is­raeli biotech try­ing to de­vel­op a treat­ment to re­duce in­fec­tions stem­ming from surgery faced se­ri­ous in­vestor back­lash Fri­day af­ter a Phase III fail …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER